Le Lézard
Classified in: Health
Subjects: PER, MAT

InMed Announces Election of Directors


VANCOUVER, BC, Nov. 24, 2020 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ:INM) (TSX:IN), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol ("CBN"), today confirmed that, at its annual general and special meeting of shareholders held on November 20, 2020 (the "Meeting"), all of the matters put forward before shareholders for consideration and approval as set out in InMed's notice of meeting and management information circular, dated October 7, 2020, were approved by the shareholders. In particular, shareholders approved the election of all director nominees to hold office until the next annual meeting of shareholders or until their successors are elected or appointed. Results of the vote for the election of directors at the Meeting are set out as follows:

Director

Votes For


Withheld Votes

Number

Percentage


Number

Percentage

Eric A. Adams

639,176

90.84%


64,464

9.16%

Adam Cutler

654,431

93.01%


49,209

6.99%

William J. Garner

644,945

91.66%


58,695

8.34%

Andrew Hull

654,149

92.97%


49,491

7.03%

Catherine Sazdanoff

653,532

92.88%


50,108

7.12%

InMed filed a report of voting results on SEDAR at www.sedar.com on November 24, 2020.

About InMed: InMed Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of cannabinoid-based medications, initially focused on the therapeutic benefits of cannabinol (CBN) in diseases with high unmet medical need. The Company is dedicated to delivering new therapeutic alternatives to patients that may benefit from cannabinoid-based medicines. For more information, visit www.inmedpharma.com.

Cautionary Note Regarding Forward-Looking Information:

This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities laws. Forward-looking information is based on management's current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Forward-looking information in this news release includes statements about: leading the way in the clinical development of CBN; developing a pipeline of cannabinoid-based medications in diseases with high unmet medical need; and delivering new therapeutic alternatives to patients that may benefit from cannabinoid-based medicines.

All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.

NEITHER THE TORONTO STOCK EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

SOURCE InMed Pharmaceuticals Inc.


These press releases may also interest you

at 21:18
"These national findings demonstrate the critical need to ensure that equity is a part of all efforts to ensure information and access to services for women. Our findings reveal that Hispanic and Black women are not getting the information they need...

at 20:47
Legend Labz, Inc. announced today a license agreement with The University of California to produce a breakthrough muscle supplement, which lab studies show can increase muscle mass gains by more than 200 percent.   New...

at 20:27
Ortho Clinical Diagnostics Holdings plc ("Ortho"), the world's largest pure-play in vitro diagnostics company dedicated to improving and saving lives through innovative laboratory testing and blood-typing solutions, today announced the pricing of its...

at 19:48
Three CityHealth COVID-19 testing locations in Sacramento, San Francisco, and Oakland have been badly damaged by last night's storms in the Bay area. In addition, one already damaged location was the victim of theft which resulted in the loss of...

at 19:00
Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in class therapeutics in hematology and oncology,...

at 18:34
DuPont  announced today that the final exchange ratio for its exchange offer will be 0.7180 shares of common stock of Nutrition & Biosciences, Inc. ("N&B") for each share of DuPont common stock that is validly tendered and not properly withdrawn and...



News published on 24 november 2020 at 20:00 and distributed by: